Electrochemotherapy - A locoregional therapy with well-established palliative effect in patient with large recurrent lesion of head and neck

被引:11
|
作者
Pichi, Barbara [1 ]
Pellini, Raul [1 ]
Spriano, Giuseppe [1 ]
机构
[1] IRCSS Natl Canc Inst Regina Elena, Dept Otolaryngol Head & Neck Surg, Via Elio Chianesi 53, I-00144 Rome, Italy
关键词
Electrochemotherapy; Head and neck cancer; Palliation; Supportive care; Quality of life; STANDARD OPERATING PROCEDURES; SQUAMOUS-CELL CARCINOMA; ELECTROPORATION THERAPY; EUROPEAN RESEARCH; NONMELANOMA HEAD; ORAL-CAVITY; CANCERS; BLEOMYCIN; CISPLATIN; ONCOLOGY;
D O I
10.1016/j.jcms.2018.10.014
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Electrochemotherapy (ECT) is a well established treatment strategy for skin tumors of different histology. The aim of this study was to evaluate the feasibility and efficacy of electrochemotherapy in the palliative setting in patients with head and neck malignancies, already treated with surgery and/or radio-chemotherapy with no other therapeutic option. Methods: Thirty-six patients with a loco-regional M0/M1 relapse with no other therapeutic option not suitable for a cure with a radical intent by surgery or RT and not suitable for systemic therapy and/or already treated with it, were admitted to electrochemotherapy (ECT) protocol treatment. ECT was performed according ESOPE guidelines. Clinical features, treatment response, and adverse effects were evaluated 15, 30 days and then every months after the treatment. Results: An overall response of 100% was observed. Only 3 patients out 36 showed a CR. Overall survival probability at 12 months was 41.6% (median OS: 9 months). In all patient, an improvement of quality of life in terms of pain, bleeding events were observed, while need for medical assistance or dressing was significantly reduced 1 month after electrochemotherapy (p < 0.001). Conclusions: Electrochemotherapy is an effective palliative treatment of non-resectable head and neck malignancies able. Due to the ECT limited side effects, its early use would be desirable to obtain a better local control of the disease and improve quality of life of patients. (C) 2018 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 36 条
  • [21] Outcome of patients treated with palliative weekly Paclitaxel plus Cetuximab in recurrent head and neck cancer after failure of platinum-based therapy
    Aaron E. Sosa
    Juan J. Grau
    Luis Feliz
    Verónica Pereira
    Diego Alcaraz
    Carmen Muñoz-García
    Miguel Caballero
    European Archives of Oto-Rhino-Laryngology, 2014, 271 : 373 - 378
  • [22] Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy
    Sosa, A. E.
    Grau, J. J.
    Feliz, L. R.
    Pereira, M. V.
    Alcaraz, D. W.
    Munoz-Garcia, C.
    Caballero, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S767 - S767
  • [23] INVOLVED-LESION RADIATION THERAPY AFTER CHEMOTHERAPY IN LIMITED-STAGE HEAD-AND-NECK DIFFUSE LARGE B CELL LYMPHOMA
    Yu, Jeong Il
    Nam, Heerim
    Ahn, Yong Chan
    Kim, Won Seog
    Park, Keunchil
    Kim, Seok Jin
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (02): : 507 - 512
  • [24] The effect of matrices on the gene expression profile of patient-derived head and neck carcinoma cells for in vitro therapy testing
    Hyytiainen, Aini
    Korelin, Katja
    Toriseva, Mervi
    Wilkman, Tommy
    Kainulainen, Satu
    Mesimaki, Karri
    Routila, Johannes
    Ventela, Sami
    Irjala, Heikki
    Nees, Matthias
    Al-Samadi, Ahmed
    Salo, Tuula
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [25] The effect of matrices on the gene expression profile of patient-derived head and neck carcinoma cells for in vitro therapy testing
    Aini Hyytiäinen
    Katja Korelin
    Mervi Toriseva
    Tommy Wilkman
    Satu Kainulainen
    Karri Mesimäki
    Johannes Routila
    Sami Ventelä
    Heikki Irjala
    Matthias Nees
    Ahmed Al-Samadi
    Tuula Salo
    Cancer Cell International, 23
  • [26] ENTERAL FEEDING INCREASES THE WELL-BEING FOR PATIENTS WITH HEAD AND NECK CANCER UNDERGOING RADIATION THERAPY AND LOWER THE COST IN OUT-PATIENT CARE
    Goransson, H.
    Rolin, E.
    Wedmark, C.
    RADIOTHERAPY AND ONCOLOGY, 2011, 98 : S38 - S38
  • [27] Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck Cancer
    Thomas, Joel
    Wang, Hong
    Clump, David A.
    Ferris, Robert L.
    Duvvuri, Umamaheswar
    Ohr, James
    Heron, Dwight E.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [28] Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.
    Kim, Hana
    Ahn, Myung-Ju
    Oh, Dongryul
    Park, Sehhoon
    Jung, Hyun Ae
    Lee, Se-Hoon
    Park, Keunchil
    Ahn, Yong Chan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review
    Choi, Jonathan S.
    Sansoni, Eugene R.
    Lovin, Benjamin D.
    Lindquist, Nathan R.
    Phan, Jack
    Mayo, Lauren L.
    Ferrarotto, Renata
    Su, Shirley Y.
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2020, 129 (05): : 517 - 522
  • [30] EGFR-gerichtete palliativeTherapie mit Panitumumab bei rezidivierten und/oder metastasierten Kopf-Hals-TumorenSPECTRUM-StudieEGFR-targeted palliative therapy with panitumumab in recurrent and/or metastatic head and neck cancerThe SPECTRUM study
    M. Knödler
    C. Mozet
    Der Onkologe, 2013, 19 (12): : 1074 - 1075